{"id":160,"date":"2019-08-28T15:57:02","date_gmt":"2019-08-28T19:57:02","guid":{"rendered":"http:\/\/blogs.duanemorris.com\/lifescienceslaw\/?p=160"},"modified":"2019-08-28T15:57:02","modified_gmt":"2019-08-28T19:57:02","slug":"much-of-oklahomas-572-million-opioid-case-likely-to-be-replicated-elsewhere-but-unique-cause-of-action-may-not","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2019\/08\/28\/much-of-oklahomas-572-million-opioid-case-likely-to-be-replicated-elsewhere-but-unique-cause-of-action-may-not\/","title":{"rendered":"Much of Oklahoma&#8217;s $572 Million Opioid Case Likely to Be Replicated Elsewhere, But Unique Cause of Action May Not"},"content":{"rendered":"<p>On August 26, 2019, Cleveland County, Oklahoma, District Judge Thad Balkman delivered his highly anticipated ruling in the state of Oklahoma\u2019s lawsuit against certain pharmaceutical companies responsible for manufacturing and marketing prescription opioid medications. Because the other pharmaceutical companies named in the state\u2019s case settled with the Attorney General\u2019s Office earlier this year, Johnson &amp; Johnson and its subsidiary Janssen Pharmaceuticals remained the primary subjects of the evidence at trial and the focus of the attention surrounding Judge Balkman\u2019s then-forthcoming ruling.<\/p>\n<p>As Judge Balkman stated in the published\u00a0<a title=\"State of Oklahoma v. Johnson &amp; Johnson et al.\" href=\"https:\/\/int.nyt.com\/data\/documenthelper\/1660-oklahoma-opioid-trial-johnson-and-johnson\/79f3fe55f5fa1a75bd48\/optimized\/full.pdf#page=1\" target=\"_blank\" rel=\"noopener noreferrer\">judgment<\/a>, the defendants knowingly and misleadingly marketed their highly addictive prescription opioids, and by doing so caused harm for which the state could seek redress, as their \u201cactions annoyed, injured, or endangered the comfort, repose, health or safety of Oklahomans.\u201d<\/p>\n<p><a href=\"https:\/\/www.duanemorris.com\/alerts\/much_oklahomas_$572_million_opioid_case_likely_replicated_elsewhere_0819.html\">View the full <em>Alert<\/em> on the Duane Morris LLP website<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>On August 26, 2019, Cleveland County, Oklahoma, District Judge Thad Balkman delivered his highly anticipated ruling in the state of Oklahoma\u2019s lawsuit against certain pharmaceutical companies responsible for manufacturing and marketing prescription opioid medications. Because the other pharmaceutical companies named in the state\u2019s case settled with the Attorney General\u2019s Office earlier this year, Johnson &amp; &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/2019\/08\/28\/much-of-oklahomas-572-million-opioid-case-likely-to-be-replicated-elsewhere-but-unique-cause-of-action-may-not\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Much of Oklahoma&#8217;s $572 Million Opioid Case Likely to Be Replicated Elsewhere, But Unique Cause of Action May Not&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[392,388,396,395,393,394,322],"ppma_author":[521],"class_list":["post-160","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-dana-ash","tag-justin-stern","tag-nuisance-law","tag-oklahoma","tag-opioid","tag-opioid-epidemic","tag-pharmaceuticals"],"authors":[{"term_id":521,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/comments?post=160"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/posts\/160\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/media?parent=160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/categories?post=160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/tags?post=160"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/lifescienceslaw\/wp-json\/wp\/v2\/ppma_author?post=160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}